drugset / Trial / NCT05815901
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
A phase 3 clinical trial to compare and evaluate efficacy and safety of epaminurad with febuxostat in gout patients.
Timeline
- Start
- 2023-03-21
- Primary completion
- 2024-03-26
- Completion
- 2026-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epaminurad | Small molecule | 6 mg | — |
| Subject | Epaminurad | Small molecule | 9 mg | — |
| Comparator | Febuxostat | Small molecule | 40 mg | — |
| Comparator | Febuxostat | Small molecule | 80 mg | — |